Searched for
GLIVEC VERDICT
US industry reviewing Supreme Court decision on NovartisUSIBC expressed its unease over SC on denying a patent on Glivec and said that this would impact innovation and investment climate in India.03 Apr, 2013, 11.30 AM IST- Novartis lost patent case on technical groundNovartis lost its case on technical grounds. It failed to establish that the drug’s new form was sufficiently patentable.02 Apr, 2013, 08.18 AM IST
- Novartis order may force pharma MNCs to changeThe ruling ends Novartis' attempts to secure a patent for the drug and continues to keep the price of anti-blood cancer drugs low in the co...02 Apr, 2013, 04.00 AM IST
- 'Glivec patent denial to hit investment in medical advancement'SC's decision to deny patent to Novartis will negatively impact the investment in medical, tech advancements, the US Chamber of Commerce sa...01 Apr, 2013, 10.20 PM IST
- Pharma stocks rally after SC's Novartis verdict; analysts positive on DRL, Cipla, NatcoPharma stocks surged 2-5 per cent after the Supreme Court dismissed Novartis AG's plea for getting its blood cancer drug patented in India.01 Apr, 2013, 04.29 PM IST
- Novartis tanks 7%, hits 52-week low as SC denies cancer drug patentOther pharmaceutical companies like Natco Pharma, Cipla and Ranbaxy surged 2-5% after the SC denied patent for Novartis' cancer drug Glivec.01 Apr, 2013, 12.38 PM IST
- Glivec patent: All eyes on SC today; ruling to decide what can be patented in IndiaOn Monday, the Supreme Court is scheduled to pronounce its verdict on a case that will have profound implications on what can or cannot be ...01 Apr, 2013, 10.50 AM IST
- Novartis fears it may lose Glivec case in Supreme CourtThe Supreme Court is slated to announce a verdict in the case filed by Novartis in 2006 against the Indian government, challenging a key pu...28 Mar, 2013, 05.54 AM IST
- Natco’s compulsory licence for selling generic copies of Bayer’s cancer drug Nexavar upheld by IpabThe Indian patents appeals board had last year dismissed Bayer’s petition seeking a stay on the “compulsory licence” issued to Natco.05 Mar, 2013, 03.37 AM IST
- Cipla’s patent win against Roche boosts hopes of generic drugmakersThe Delhi HC ruling favouring India’s second largest drugmaker Cipla has come as a shot in the arm for other generic makers who are fightin...10 Sep, 2012, 11.15 AM IST
- Fifteen stocks likely to be in focus in Tuesday morning tradeThe 50-share Nifty is likely to trade in a range with a negative bias on Tuesday tracking weak Asian markets.21 Aug, 2012, 07.40 AM IST
- Indian generic drug firms - pharma MNC patent fight to determine price of medicinesWarring Indian generic drug firms and patent heavy pharma MNCs are closely watching two landmark patent cases. The verdicts will play a hug...18 Sep, 2011, 07.02 AM IST
- Complete formalities on Novartis patent claim: SCThe Supreme Court on Friday directed the Centre, Cipla, Ranbaxy, Hetero Drugs, Natco Pharma and others to complete their pleadings in the m...03 Dec, 2010, 07.39 PM IST
- Novartis puts R&D activities in India on holdMUMBAI: Frustrated with patent challenges, Swiss-pharma giant Novartis has put its research and development (R&D) activities in India on th...12 Nov, 2009, 12.49 AM IST
- Cipla scores a generic win over RocheThe Delhi HC rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing generic versions of anti-cancer drug...20 Mar, 2008, 02.00 AM IST
- Fine judgeEven while somebody bays for his blood, S Chandrasekaran can be calm and imperturbable.09 Aug, 2007, 03.46 AM IST
- Novartis plea on patents struck downThe Madras High Court dismissed a petition by Swiss pharmaceutical giant Novartis challenging the constitutionality of Section 3(d) of the ...07 Aug, 2007, 01.07 AM IST
Load More
